Additional Resources

New data regarding the prevention, diagnosis, and management of COVID-19 are emerging daily. Please see the list of COVID-19 resources for healthcare professionals provided below for additional up-to-date and comprehensive information.

Resources CDC, HHS, NIH, and WHO

US Department of Health and Human Services (HHS). Find ways to prevent, treat or help fight COVID-19. https://combatcovid.hhs.gov/

National Institutes of Health (NIH). COVID-19 Treatment Guidelines. https://covid19treatmentguidelines.nih.gov/introduction/

Centers for Disease Control and Prevention (CDC). Evaluating and Testing Persons for Coronavirus Disease 2019 (COVID-19). https://www.cdc.gov/coronavirus/2019-nCoV/hcp/clinical-criteria.html

CDC. Interim Clinical Guidance for Management of Patients with Confirmed Coronavirus Disease (COVID-19). https://www.cdc.gov/coronavirus/2019-ncov/hcp/clinical-guidance-management-patients.html

NIH. COVID-19 Treatment Guidelines. https://covid19treatmentguidelines.nih.gov/introduction/

CDC. Information for Healthcare Professionals about Coronavirus (COVID-19). https://www.cdc.gov/coronavirus/2019-nCoV/hcp/index.html

World Health Organization (WHO). Country & Technical Guidance – Coronavirus disease (COVID-19). https://www.who.int/emergencies/diseases/novel-coronavirus-2019/technical-guidance

Additional Guidance on the Management of Patients with COVID-19.

Society of Critical Care Medicine. Surviving Sepsis Campaign: COVID-19 Guidelines. https://www.sccm.org/SurvivingSepsisCampaign/Guidelines/COVID-19

Infectious Disease Society of America (IDSA). COVID-19 Resource Center. https://www.idsociety.org/public-health/COVID-19-Resource-Center/

IDSA. Infectious Diseases Society of America Guidelines on Infection Prevention in Patients with Suspected or Known COVID-19. https://www.idsociety.org/practice-guideline/covid-19-guideline-infection-prevention/

Recommendations on the Management of Special Populations During the COVID-19 Pandemic.

Al-Shamsi HO, Alhazzani W, Alhuraiji A, et al. A practical approach to the management of cancer patients during the novel coronavirus disease 2019 (COVID-19) pandemic: an international collaborative group. Oncologist. 2020. https://doi.org/10.1634/theoncologist.2020-0213

American College of Surgeons (ACS). Recommendations for prioritization, treatment and triage of breast cancer patients during the COVID-19 pandemic. Available at https://www.facs.org/quality-programs/cancer/executive-summary

American Society of Clinical Oncology (ASCO). COVID-19 Patient Care Information. https://www.asco.org/asco-coronavirus-information/care-individuals-cancer-during-covid-19

Centers for Disease Control and Prevention (CDC). Considerations for Inpatient Obstetric Healthcare Settings. https://www.cdc.gov/coronavirus/2019-ncov/hcp/inpatient-obstetric-healthcare-guidance.html

American College of Obstetricians and Gynecologists (ACOG). Novel Coronavirus 2019 (COVID-19). https://www.acog.org/clinical/clinical-guidance/practice-advisory/articles/2020/03/novel-coronavirus-2019

Supporting Patient Journeys Through Resources and Tools to Promote Positive Patient Outcomes in Care

National Infusion Center Association. COVID-19 Antibody Therapies Resource Center. https://infusioncenter.org/infusion_resources/covid-19-antibody-treatment-resource-center/

CombatCOVID.hhs.gov. Monoclonal Antibodies for High-Risk COVID-19 Positive Patients. https://combatcovid.hhs.gov/i-have-covid-19-now/monoclonal-antibodies-high-risk-covid-19-positive-patients?gclid=EAIaIQobChMI4r-5loX27gIVCaiGCh3AQgwgEAAYASAAEgI76fD_BwE

Joost Wiersinga W, et al. Pathophysiology, transmission, diagnosis, and treatment of coronavirus disease 2019 (COVID-19): A review. JAMA. 2020;10.1001/jama.2020.12839. https://pubmed.ncbi.nlm.nih.gov/32648899/

Guan WJ, et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med. 2020;382:1708-1720. https://pubmed.ncbi.nlm.nih.gov/32109013/

Rothan HA, et al. The epidemiology and pathogenesis of coronavirus disease (COVID-19) outbreak. J Autoimmun. 2020;109:102433. https://pubmed.ncbi.nlm.nih.gov/32113704/

Lechien JR, et al. Clinical and epidemiological characteristics of 1420 European patients with mild-to-moderate coronavirus disease 2019. [published online ahead of print, 2020 Apr 30]. J Intern Med. 2020; 10.1111/joim.13089. https://pubmed.ncbi.nlm.nih.gov/32352202/

Wang W, et al. Updated understanding of the outbreak of 2019 novel coronavirus (2019-nCoV) in Wuhan, China. J Med Virol. 2020;92:441-447. https://pubmed.ncbi.nlm.nih.gov/31994742/

Wu Z, et al. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: Summary of a report of 72 314 cases from the Chinese Center for Disease Control and Prevention. JAMA. 2020;323:1239-1242. https://jamanetwork.com/journals/jama/fullarticle/2762130

Richardson S, et al. Presenting characteristics, comorbidities, and outcomes among 5700 patients hospitalized with COVID-19 in the New York City area. JAMA. 2020 May 26;323:2052–2059. https://pubmed.ncbi.nlm.nih.gov/32320003/

Docherty AB, et al. Features of 20,133 UK patients in hospital with COVID-19 using the ISARIC WHO Clinical Characterisation Protocol: Prospective observational cohort study. BMJ. 2020;369:m1985. https://www.bmj.com/content/369/bmj.m1985

Yuan X, et al. Changes of hematological and immunological parameters in COVID-19 patients. [published online ahead of print, 2020 Jul 12]. Int J Hematol. 2020;1-7. https://pubmed.ncbi.nlm.nih.gov/32656638/

Bhimraj A, et al. Infectious Diseases Society of America Guidelines on the Treatment and Management of Patients with COVID-19. IDSA Guidelines. V2.1.0. https://www.idsociety.org/practice-guideline/covid-19-guideline-treatment-and-management/

Alhazzani W, et al. Surviving Sepsis Campaign: Guidelines on the management of critically ill adults with coronavirus disease 2019 (COVID-19). Intensive Care Med. 2020;46:854-887. https://pubmed.ncbi.nlm.nih.gov/32222812/

World Health Organization (WHO). Clinical management of COVID-19. Interim Guidance. 2020 May 27. https://www.who.int/publications/i/item/clinical-management-of-covid-19

National Institutes of Health (NIH). COVID-19 Treatment Guidelines. https://www.covid19treatmentguidelines.nih.gov/

Beigel JH, et al. Remdesivir for the treatment of COVID-19 – Final Report. N Engl J Med. 2020;383:1813-1826. https://www.nejm.org/doi/full/10.1056/NEJMoa2007764

Spinner CD, et al. Effect of remdesivir vs standard care on clinical status at 11 days in patients with moderate COVID-19: a randomized clinical trial. JAMA. 2020;324:1048-1057. https://jamanetwork.com/journals/jama/fullarticle/2769871

Horby P, et al. Dexamethasone in hospitalized patients with COVID-19 – preliminary report. N Engl J Med. 2020;Epub ahead of print. https://pubmed.ncbi.nlm.nih.gov/32678530/

Siddiqi HK, et al. COVID-19 illness in native and immunosuppressed states: A clinical-therapeutic staging proposal. J Heart Lung Transplant. 2020;39:405-407. https://www.jhltonline.org/article/S1053-2498(20)31473-X/fulltext

Li L, et al. Effect of convalescent plasma therapy on time to clinical improvement in patients with severe and life-threatening COVID-19: A randomized clinical trial. [published online ahead of print, 2020 Jun 3].JAMA. 2020;e2010044. https://pubmed.ncbi.nlm.nih.gov/32492084/

Kalil AC, et al. Baricitinib plus remdesivir for hospitalized adults with COVID-19. N Engl J Med. 2020;Epub ahead of print. https://www.nejm.org/doi/full/10.1056/NEJMoa2031994

Baum A, et al. Antibody cocktail to SARS-CoV-2 spike protein prevents rapid mutational escape seen with individual antibodies. Science. 2020;369:1014-1018. https://pubmed.ncbi.nlm.nih.gov/32540904/

Gandhi RT, et al. Mild or moderate COVID-19. N Engl J Med. 2020;383:1757-1766. https://pubmed.ncbi.nlm.nih.gov/32329974/

Docherty AB, et al. Features of 20 133 UK patients in hospital with covid-19 using the ISARIC WHO Clinical Characterisation Protocol: prospective observational cohort study. BMJ. 2020;369:m1985. https://pubmed.ncbi.nlm.nih.gov/32444460/

Simonovich VA, et al. A Randomized Trial of Convalescent Plasma in Covid-19 Severe Pneumonia. N Engl J Med. 2020;Epub ahead of print. https://pubmed.ncbi.nlm.nih.gov/33232588/

Fact Sheet for Health Care Providers Emergency Use Authorization (EUA) of Baricitinib. https://www.fda.gov/media/143823/download

Fact Sheet for Health Care Providers Emergency Use Authorization (EUA) of Bamlanivimab. http://pi.lilly.com/eua/bamlanivimab-eua-factsheet-hcp.pdf

Fact Sheet for Health Providers Emergency Use Authorization (EUA) of Bamlanivimab and Etesevimab. https://www.fda.gov/media/145802/download

Fact Sheet for Health Care Providers Emergency Use Authorization (EUA) of Casirivimab and Imdevimab. https://www.fda.gov/media/143892/download

Fact Sheet for Health Care Providers Emergency Use Authorization (EUA) of COVID-19 Convalescent Plasma for Treatment of Hospitalized Patients with COVID-19. https://www.fda.gov/media/141478/download

Weinreich DM, et al. REGN-COV2, a neutralizing antibody cocktail, in outpatients with COVID-29. N Engl J Med. 2020;Epub ahead of print. https://www.nejm.org/doi/pdf/10.1056/NEJMoa2035002

Gottlieb RL, et al. Effect of bamlanivimab as monotherapy or in combination with etesevimab on viral load in patients with mild to moderate COVID-19: a randomized clinical trial. JAMA. 2021;325:632-644. https://jamanetwork.com/journals/jama/fullarticle/2775647

Chen P, et al. SARS-CoV-2 Neutralizing Antibody LY-CoV555 in Outpatients with Covid-19. N Engl J Med. 2020;Epub ahead of print. https://www.nejm.org/doi/full/10.1056/NEJMoa2029849

ACTIV-3/TICO LY-CoV555 Study Group. A neutralizing monoclonal antibody for hospitalized patients with COVID-19. N Engl J Med. 2020;Epub ahead of print. https://www.nejm.org/doi/full/10.1056/NEJMoa2033130

Hansen J, et al. Studies in humanized mice and convalescent humans yield a SARS-CoV-2 antibody cocktail. Science. 2020;369:1010-1014. https://science.sciencemag.org/content/369/6506/1010

Callaway E. The coronavirus is mutating – does it matter? Nature. 2020;585:174-177. https://www.nature.com/articles/d41586-020-02544-6

Menu

Clinical Toolkit

The COVID-19 Clinical Toolkit is an online tool that aims to provide clinicians with up-to-date information on the presentation, prognosis, pathophysiology, and treatment strategies for COVID-19. Click on one of the options below to learn more.

This activity is provided by Med Learning Group. This activity is co-provided by Ultimate Medical Academy/CCM.
This activity is supported by educational grants from AbbVie, Astellas, Genentech, Lilly, Merck & Co., Inc., Pfizer and Regeneron Pharmaceuticals, Inc.

Copyright © 2019 | COVID Frontline | All Rights Reserved | Website by Divigner

Updates in the Treatment and Prevention of COVID-19​

Subcutaneous Administration of Casirivimab and Imdevimab Reduced the Risk of Symptomatic COVID-19 by 81% Among Household Contacts

Top-line results from a phase 3 trial showed that the combination of casirivimab and imdevimab reduced the risk of symptomatic infections by 81% among household contacts of SARS-CoV-2 infected individuals. The trial enrolled 1,505 individuals who did not have COVID-19 symptoms or anti-SARS-CoV-2 antibodies, but who lived in the same household as an individual who tested positive for SARS-CoV-2 within the prior 4 days. A single subcutaneous injection of casirivimab and imdevimab provided rapid protection to those with exposure to SARS-CoV-2 at home, with protection against symptomatic infections ranging from 72% in the first week to 93% in subsequent weeks. Individuals who developed symptomatic infections despite casirivimab and imdevimab therapy had a shorter duration of symptoms compared with those who received placebo (1 week vs 3 weeks, respectively). Infected individuals who received therapy also cleared the virus faster. Adverse events (AEs) occurred in 20% of patients receiving casirivimab and imdevimab and 29% of patients receiving placebo. Injection site reactions, all of which were grades 1-2, occurred in 4% of patients in the treatment group and 2% of placebo participants.

Casirivimab and Imdevimab Significantly Reduced Progression to Symptomatic COVID-19 in Recently Infected Asymptomatic Patients

In a phase 3 trial of 204 recently infected asymptomatic COVID-19 patients, subcutaneous administration of casirivimab and imdevimab reduced the overall risk of progressing to symptomatic COVID-19 by 31%, and by 76% after the third day. In addition to reducing the risk of symptomatic infections, the top-line results report that the combination of casirivimab and imdevimab shortened the total number of weeks patients experienced symptoms by 45% and reduced the viral burden by more than 90%. No patients withdrew from the trial due to AEs in either group. Casirivimab and imdevimab are investigational drugs with emergency use authorization for the treatment of individuals with mild-to-moderate COVID-19 who are at high-risk of progressing to severe COVID-19 or hospitalization. Casirivimab and imdevimab (REGEN-COV™) continues to be evaluated in clinical trials in multiple settings for COVID-19, including the open-label RECOVERY trial of hospitalized patients in the UK.

Johnson & Johnson COVID-19 Vaccine Administration Paused

The Centers for Disease Control and Prevention (CDC) and the Federal Drug Administration (FDA) are recommending a pause in the use of the Ad26.COV2.S vaccine developed by Johnson & Johnson (Janssen) as they review data involving 6 reported cases of a rare and severe type of blood clot in individuals after vaccination. The vaccine has been administered to more than 6.8 million individuals in the US. In all 6 reported cases, a type of blood clot called cerebral venous sinus thrombosis (CVST) occurred in combination with low platelet levels (thrombocytopenia). Treatment of CVST differs from other blood clots and administration of heparin may be dangerous in these patients. All 6 cases occurred among women aged 18 to 48 years and symptoms usually occurred 6 to 13 days after vaccination. People who develop severe headache, abdominal pain, leg pain, or shortness of breath within 3 weeks after vaccination should contact their healthcare provider.

References:

Regeneron Press Release. Phase 3 Prevention Trial Showed 81% Reduced Risk of Symptomatic SARS-CoV-2 Infections with Subcutaneous Administration of REGEN-COV™ (Casirivimab and Imdevimab). April 12, 2021. Available at: https://investor.regeneron.com/news-releases/news-release-details/phase-3-prevention-trial-showed-81-reduced-risk-symptomatic-sars

Regeneron Press Release. Phase 3 Treatment Trial in Recently Infected Asymptomatic Patients Showed REGEN-COV™ (Casirivimab and Imdevimab) Significantly Reduced Progression to Symptomatic COVID-19. April 12, 2021. Available at: https://investor.regeneron.com/news-releases/news-release-details/phase-3-treatment-trial-recently-infected-asymptomatic-patients

FDA Statement. Joint CDC and FDA Statement on Johnson & Johnson COVID-19 Vaccine. April 13, 2021. Available at: https://www.fda.gov/news-events/press-announcements/joint-cdc-and-fda-statement-johnson-johnson-covid-19-vaccine